Requires health plans that provide prescription benefits to cover at least one type of glucagon auto-injector, nasal spray, or formulation that does not require reconstitution to treat hypoglycemia. No copayment or deductible would be required.

# The Matthew Federico Diabetic Safety Act

This bill would require health insurance plans in Rhode Island that cover prescription drugs to also cover at least one type of easy-to-use glucagon product for treating hypoglycemia (dangerously low blood sugar). Specifically, the covered products would include glucagon auto-injectors, nasal sprays, or other formulations that are ready to use without needing to be mixed or prepared before administration. These types of products are important because during a low blood sugar emergency, the person experiencing it — or a bystander trying to help — may not have the time or ability to mix a medication.

A key feature of the bill is that patients would pay nothing out of pocket for these glucagon products — no copayments, coinsurance, or deductibles would apply. This means the full cost would be covered by the insurance plan.

The bill primarily affects people with diabetes who are at risk of severe low blood sugar episodes, as well as their families, caregivers, and others who might need to administer emergency treatment. It also affects health insurance companies operating in Rhode Island, which would be required to provide this coverage. The bill has been introduced in the Rhode Island House of Representatives and referred to the Health & Human Services Committee, which has recommended holding it for further study, with a hearing scheduled for January 2026.